6.00

3.07% -0.19

Harvard Bioscience Inc (HBIO)

Overview News Price History Option Chain Financials Discussions Forecast

Harvard Bioscience Inc stock is traded at $6.00, with a volume of 6,022. It is down -3.07% in the last 24 hours and down -1.32% over the past month. Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Previous Close:

$6.19

Open:

$6.2

24h Volume:

6,022

Relative Volume:

0.25

Market Cap:

$27.06M

Revenue:

$85.53M

Net Income/Loss:

$-9.78M

P/E Ratio:

-2.7332

EPS:

-2.1952

Net Cash Flow:

$1.28M

1W Performance:

-3.69%

1M Performance:

-1.32%

6M Performance:

+1.28%

1Y Performance:

+5.26%

1-Day Range:

$6.00

$6.20

1-Week Range:

$6.00

$6.28

52-Week Range:

$3.755

$9.40

Harvard Bioscience Inc Stock (HBIO) Company Profile

Name

Harvard Bioscience Inc

Sector

Healthcare (1071)

Industry

Medical Instruments & Supplies (57)

Phone

(508) 893-8999

Address

84 OCTOBER HILL RD, HOLLISTON, MA

Employee

339

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

HBIO's Discussions on Twitter

Compare HBIO vs ISRG, BDX, ALC, MDLN, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HBIO Harvard Bioscience Inc	6.00	27.06M	85.53M	-9.78M	1.28M	-2.1952
ISRG Intuitive Surgical Inc	337.50	120.92B	11.03B	3.16B	3.22B	8.7251
BDX Becton Dickinson Co	156.36	43.08B	21.37B	1.41B	3.07B	3.9437
ALC Alcon Inc	67.91	33.12B	10.63B	819.00M	1.59B	1.6577
MDLN Medline Inc	38.75	32.77B	29.14B	1.07B	1.05B	1.1956
RMD Resmed Inc	195.27	28.33B	5.54B	1.52B	1.74B	10.37

Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-10-23	Upgrade	The Benchmark Company	Speculative Buy → Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-09-20	Initiated	Northland Capital	Outperform
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-08-19	Downgrade	Janney	Buy → Neutral
Jan-24-18	Reiterated	Janney	Buy
Jan-23-18	Reiterated	The Benchmark Company	Buy
Nov-17-16	Initiated	Singular Research	Buy
Jul-28-15	Initiated	The Benchmark Company	Buy

View All

Harvard Bioscience Inc Stock (HBIO) Latest News

05:36 AM

Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de

Jul 09, 2026

Jul 07, 2026

Harvard Bioscience focuses on lab equipment growth - AD HOC NEWS

Jul 07, 2026

Jul 06, 2026

Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume TradingBollinger Walk - dars.gov.et

Jul 06, 2026

Jul 04, 2026

Harvard Bioscience | SD: Specialized disclosure report - Moomoo

Jul 04, 2026

Jun 26, 2026

Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView

Jun 26, 2026

Jun 25, 2026

HBIO Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Price to sales forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView

Jun 25, 2026

Price to earnings forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView

Jun 25, 2026

Price to book forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView

Jun 25, 2026

Enterprise value to EBITDA forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView

Jun 25, 2026